StockNews.com Downgrades Adaptimmune Therapeutics (NASDAQ:ADAP) to Buy

Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

Separately, HC Wainwright reduced their price target on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Adaptimmune Therapeutics has a consensus rating of “Buy” and an average price target of $3.16.

Adaptimmune Therapeutics Stock Performance

NASDAQ:ADAP opened at $0.59 on Thursday. Adaptimmune Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.05. The company has a market capitalization of $150.02 million, a price-to-earnings ratio of -2.67 and a beta of 2.26. The business has a 50 day moving average of $0.88 and a 200 day moving average of $1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADAP. Fullcircle Wealth LLC bought a new stake in shares of Adaptimmune Therapeutics during the third quarter valued at approximately $33,000. Vontobel Holding Ltd. grew its stake in Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after buying an additional 30,000 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Adaptimmune Therapeutics in the third quarter valued at about $95,000. Boulder Hill Capital Management LP purchased a new position in shares of Adaptimmune Therapeutics in the first quarter worth $143,000. Finally, Jane Street Group LLC lifted its position in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.